The Hartford Post
SEE OTHER BRANDS

Following the news from Connecticut

The Hartford Post: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Hartford Post.

Press releases published on April 28, 2025

Civicom’s Quillit ai®  Selects Anthropic’s Claude As Its LLM Provider For Enhanced Qualitative Research Insights

Civicom’s Quillit ai® Selects Anthropic’s Claude As Its LLM Provider For Enhanced Qualitative Research Insights

Civicom Research Services chooses Anthropic AI’s Claude as the LLM Provider for the backbone of its AI-powered report-generating tool, Quillit ai®. GREENWICH, CT, UNITED STATES, April 28, 2025 /⁨EINPresswire.com⁩/ -- Civicom, a trusted global leader in …

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first …

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation …

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service